{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "TBRG",
  "name": "TruBridge, Inc.",
  "url": "https://frontierpicks.com/dossiers/TBRG/",
  "json_url": "https://frontierpicks.com/dossiers/TBRG.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Closed and now formally deregistered: the IKS Health merger became effective 2026-07-09 at $26.25/share cash, Form 25 filed the same day, Form 15-12G on 2026-07-24. The adjusted series ends 2026-07-08 at $26.24. A screen still surfacing TBRG at RSI 75 and 0.0% off its 52-week high is reading a terminated tape, not an accelerating one.",
  "invalidation_trigger": "A daily close below $26.25 cannot print — the adjusted series ends 2026-07-08 at $26.24, shares converted to cash at the 2026-07-09 effective time, and Form 15-12G was filed 2026-07-24. Only a new US-listed successor security would reopen the file.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "m-and-a-special-situations",
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "2026-04-23: IKS Health (sub of Inventurus Knowledge Solutions, NSE: IKS) signed definitive merger to acquire TBRG at $26.25/share cash, ~$600M equity / ~$557M EV. Expected close Q3 2026.",
    "2026-04-23: IKS Health (US sub of NSE-listed Inventurus Knowledge Solutions) signed definitive merger to acquire TBRG at $26.25/share cash via merger sub IKS Next Horizon, Inc. ~$572M gross transaction value. Expected close Q3 2026.",
    "2026-06-22: HSR antitrust waiting period EXPIRED (8-K) — last U.S. regulatory gate cleared; deal now procedural, only the 7/7 shareholder vote + TopCo Indian-law special resolution remain.",
    "2026-04-23: IKS Health (US sub of NSE-listed Inventurus Knowledge Solutions) signed definitive merger to acquire TBRG at $26.25/share cash via merger sub IKS Next Horizon, Inc. (~$572M gross). Expected close Q3 2026.",
    "2026-07-09: IKS Health completed the acquisition; TruBridge is now a wholly owned subsidiary of Inventurus Knowledge Solutions (NSE: IKS). Common stock deregistered and delisted from Nasdaq Global Select.",
    "2026-07-10: Cantor Fitzgerald suspended its Neutral rating — routine coverage termination on a closed deal, not a fundamental call.",
    "Common stock deregistered: Form 25 filed 2026-07-09, Form 15-12G filed 2026-07-24. No SEC reporting, no earnings dates, no forward price series.",
    "Any TBRG quote dated after 2026-07-08 is a stale symbol-table artifact; the last completed adjusted daily close was $26.24 on 2026-07-08.",
    "Residual TruBridge economics sit inside Inventurus Knowledge Solutions (NSE: IKS) — INR-denominated, Indian disclosure regime, no US-listed line.",
    "Cantor Fitzgerald suspended coverage 2026-07-10; no sell-side estimates or price targets exist for this ticker.",
    "Screener fields (RSI 14 at 75.0, 0.0% from the 52-week high, +49.8% 3-month) are artifacts of a tape pinned to the fixed $26.25 cash price."
  ],
  "body_markdown": "## Current Thesis\nThe file that closed on 2026-07-09 has since been closed administratively as well. TruBridge shareholders received **$26.25 per share in cash** at the merger effective time; the company filed **Form 25** with the SEC on **2026-07-09** to remove the common stock from the Nasdaq Global Select Market, and **Form 15-12G on 2026-07-24**, terminating Section 12(g) registration and suspending reporting obligations. TruBridge is a wholly owned subsidiary of Inventurus Knowledge Solutions (NSE: IKS). There is no US-listed equity to price, no filing stream, and no forward series to mark. What has changed since the last note is on the acquirer's side: IKS reported Q1 FY27 on **2026-08-06** and gave the first post-close commentary on what it bought.\n\n## Bull Case\n- **The cash was paid at the signed number.** $26.25/share, the exact consideration in the 2026-04-23 merger agreement — no collar, no stock leg, no earnout.\n- **No dissent to litigate.** No holder exercised appraisal rights, despite a 2026-05-10 commentary piece arguing the fixed-cash terms undervalued the equity and forced a tax event. For a sub-$600M take-private that is an unusually clean exit path.\n- **The financing closed and was then termed out.** Press coverage dated **2026-08-03** reports IKS finalising a syndication of the acquisition funding behind the ~$557M purchase, following the up-to-$670M commitment from Citigroup, Deutsche Bank, JPMorgan and Citibank. Any residual scenario in which funding failure unwound the transaction is gone.\n- **The acquirer has put a number on the asset.** On the **2026-08-06** Q1 FY27 release, IKS reported consolidated operating revenue of **₹893.63 crore, +21% YoY** (12% constant currency) and PAT of **₹194 crore vs ₹152 crore** a year earlier, with EBITDA margin **33% reported / 35% adjusted for one-time TruBridge acquisition costs**, and stated it inherited roughly **$68M of annualised EBITDA** with TruBridge. Note that the quarter ended 2026-06-30, before the 2026-07-09 close — the revenue line does not yet include TruBridge; the transaction costs do. That is an inference from the reporting calendar, not a company statement.\n\n## Bear Case\n- **Nothing remains to own.** Registration terminated 2026-07-24. Any vendor still quoting TBRG is serving a stale symbol table.\n- **The successor is out of reach for a US-brokerage book.** TruBridge economics now sit inside an NSE-listed Indian mid-cap, INR-denominated, on a different disclosure regime and reporting calendar — a different risk object from the one this ticker described.\n- **The whole re-rate happened inside one halt.** From the ~$16.24 pre-rumour standalone close (2026-04-02) to the cash cap in a single session: halted 9:21:59 a.m. ET on 2026-04-23, resumed 10:00 a.m. ET. No accumulation, no retest, no leg.\n- **Post-signing the payoff shape was ~$0.20 to the cap against ~$10 to the pre-rumour level** — the structural reason the name never behaved like momentum after 2026-04-23.\n- **Coverage is gone.** Cantor Fitzgerald suspended its Neutral rating on 2026-07-10, the routine termination after a completed take-private. No estimates, no targets, no updates.\n\n## Setup & Price Structure\n- **The narrative is dead.** Dated by 2026-07-09 (effective time, trading ceased before the open, Form 25 filed) and 2026-07-24 (Form 15-12G). Not maturing, not saturated — terminated.\n- **Last completed adjusted daily close: $26.24 on 2026-07-08**, one cent under the fixed $26.25 cash price. The 52-week high in the same series is $26.25.\n- **Screener fields are frozen artifacts.** RSI(14) 75.0, three-month return +49.8%, 0.0% below the 52-week high — all computed off bars that stop on 2026-07-08 against a price pinned to a merger number. A momentum ranker reads that as strength; it is the arithmetic of a tape that ended.\n- **Crowding and positioning evidence is absent by construction**, and that absence is the observable: no public float (the survivor is wholly owned), no post-2026-07-09 short-interest print, no options chain, no scheduled earnings date, no sell-side estimates after the 2026-07-10 coverage suspension. There is no bid to be thin or thick.\n\n## Catalyst Calendar (next 30 days)\n- **2026-08-15 → 2026-09-14: nothing dated.** No earnings, no SEC filings (reporting obligations suspended on the 2026-07-24 Form 15-12G), no exchange or index events for this symbol.\n- **~2026-11-14 (est.) — IKS (NSE: IKS) Q2 FY27 results.** Outside the window. This is the first reporting period that includes TruBridge post-close; the date is estimated from the quarterly cadence that produced the 2026-08-06 Q1 release, not company-confirmed.\n\n## What Would Change Our Mind\nThe structure that would have to reappear is a listed security. Concretely: a Form 8-A or exchange listing notice for a TruBridge successor, an IKS carve-out or re-IPO of the US assets filed on an S-1, or a US depositary line on Inventurus Knowledge Solutions — none of which exists today. Absent that, the gradeable form of this read is that **a daily close below $26.25 cannot print**: the adjusted series ends 2026-07-08 at $26.24 and the equity converted to cash the following morning. A second condition worth watching is symbol reuse — Nasdaq can reassign a retired ticker, and a TBRG quote appearing without a matching listing filing should be treated as a different issuer or a data artifact, not a resumption. If IKS's Q2 FY27 report shows TruBridge revenue materially below the ~$68M annualised EBITDA framing given on 2026-08-06, that is information about the acquirer's equity, not about a security anyone here can price.\n\n## Correlation Notes\n- **No US-listed correlate remains.** The residual exposure is an INR-denominated NSE mid-cap; USD/INR and Indian mid-cap flows are now inputs on a risk object a US reader was not previously carrying.\n- That is a live datapoint for other small-cap US health-IT and revenue-cycle names being modelled as cross-border takeout candidates.\n- **Data-asset framing.** On the 2026-08-06 call IKS described building proprietary small language models on TruBridge's 5 million-plus patient dataset. Whether that framing survives contact with a P&L is an IKS question; it is the kind of claim that tends to be applied by analysts to other holders of large clinical datasets.\n- **Sleeve accounting.** For anyone tracking special-situation carry versus momentum, this name's entire return was delivered in one halted gap on 2026-04-23 and then converted to cash — it correlates with deal-completion risk, and with nothing on a chart.",
  "first_seen": "2026-04-26",
  "last_analyzed": "2026-08-15T12:03:24+00:00",
  "last_synthesized": "2026-08-15",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}